Literature DB >> 17279430

Optimised surgery (so-called TME surgery) and high-resolution MRI in the planning of treatment of rectal carcinoma.

J Strassburg1, A Lewin, K Ludwig, L Kilian, J Linke, V Loy, P Knuth, O Püttcher, U Ruehl, F Stöckmann, M Hackenthal, W Hopfenmüller, A Huppertz.   

Abstract

BACKGROUND: Since November 1998, we have applied the concept of total mesorectal excision (TME) to rectal carcinoma together with a standardised pathological quality assessment. Participation in the European MERCURY study [The MERCURY Study Group Radiology (in press), 2006] required us to establish the indication for neoadjuvant radiochemotherapy on the basis of an magnetic resonance imaging (MRI) scan. The aim of the present retrospective study is to evaluate the quality of the surgery, the efficacy of the MRI and the oncological outcomes achieved.
MATERIALS AND METHODS: Between November 2001 and October 2005, 68 out of 109 patients with carcinoma of the rectum were submitted to radical surgery in curative intent and 23/68 (34%) were given neoadjuvant therapy. In an interdisciplinary study group, each patient was evaluated pre-operatively and post-operatively using standardised MRI and histopathological methods.
RESULTS: The quality of surgery was established on the basis of the pathological examination of the surgical specimen. The rates of incomplete mesorectal excision, intra-operative tumour cell dissemination and positive circumferential margins were all low at 4%, 7% and 3%, respectively. The effectiveness of MRI proved to be greatest in predicting the tumour status at the circumferential resection margin: in the admittedly limited number of patients it proved possible to correctly predict the tumour status for every patient. The assessment of the anatomic extent of the primary tumour and of the regional lymph node metastasis according to the TNM system, in contrast, was considerably less successful at 73% and 75%, and 37% and 57%, respectively.
CONCLUSION: By applying the TME concept and MRI-based therapy planning, excellent results can be achieved and, at the same time, the number of patients requiring neoadjuvant treatment is considerably reduced.

Entities:  

Mesh:

Year:  2007        PMID: 17279430     DOI: 10.1007/s00423-007-0149-6

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  19 in total

Review 1.  Pathologic prognostic factors in the recurrence of rectal cancer.

Authors:  Carolyn C Compton
Journal:  Clin Colorectal Cancer       Date:  2002-11       Impact factor: 4.481

2.  Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging--a meta-analysis.

Authors:  Shandra Bipat; Afina S Glas; Frederik J M Slors; Aeilko H Zwinderman; Patrick M M Bossuyt; Jaap Stoker
Journal:  Radiology       Date:  2004-07-23       Impact factor: 11.105

Review 3.  Modern management of colorectal cancer--a pathologist's view.

Authors:  N J Maughan; P Quirke
Journal:  Scand J Surg       Date:  2003       Impact factor: 2.360

4.  Improved survival and local control after total mesorectal excision or D3 lymphadenectomy in the treatment of primary rectal cancer: an international analysis of 1411 patients.

Authors:  K Havenga; W E Enker; J Norstein; Y Moriya; R J Heald; H C van Houwelingen; C J van de Velde
Journal:  Eur J Surg Oncol       Date:  1999-08       Impact factor: 4.424

Review 5.  [Rectal carcinoma: is too much neoadjuvant therapy performed? Proposals for a more selective MRI based indication].

Authors:  Th Junginger; P Hermanek; K Oberholzer; H Schmidberger
Journal:  Zentralbl Chir       Date:  2006-08       Impact factor: 0.942

6.  Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging.

Authors:  G Brown; A G Radcliffe; R G Newcombe; N S Dallimore; M W Bourne; G T Williams
Journal:  Br J Surg       Date:  2003-03       Impact factor: 6.939

Review 7.  Preoperative staging of rectal cancer.

Authors:  H Kwok; I P Bissett; G L Hill
Journal:  Int J Colorectal Dis       Date:  2000-02       Impact factor: 2.571

8.  Intraoperative spillage of tumor cells in surgery for rectal cancer.

Authors:  H Zirngibl; B Husemann; P Hermanek
Journal:  Dis Colon Rectum       Date:  1990-07       Impact factor: 4.585

9.  Local recurrence in patients with rectal cancer diagnosed between 1988 and 1992: a population-based study in the west Netherlands.

Authors:  E Kapiteijn; C A Marijnen; A C Colenbrander; E Klein Kranenbarg; W H Steup; J H van Krieken; J C van Houwelingen; J W Leer; C J van de Velde
Journal:  Eur J Surg Oncol       Date:  1998-12       Impact factor: 4.424

10.  The mesorectum in rectal cancer surgery--the clue to pelvic recurrence?

Authors:  R J Heald; E M Husband; R D Ryall
Journal:  Br J Surg       Date:  1982-10       Impact factor: 6.939

View more
  9 in total

Review 1.  [Surgery for rectal cancer].

Authors:  C J Krones; M Stumpf; V Schumpelick
Journal:  Chirurg       Date:  2009-04       Impact factor: 0.955

2.  Practicability of quality goals for the treatment of rectal cancer.

Authors:  Sigmar Stelzner; Gunter Hellmich; Gunter Haroske; Erik Puffer; Thomas Jackisch; Helmut Witzigmann
Journal:  Int J Colorectal Dis       Date:  2010-06-12       Impact factor: 2.571

Review 3.  Extended abdominoperineal excision vs. standard abdominoperineal excision in rectal cancer--a systematic overview.

Authors:  Sigmar Stelzner; Carsta Koehler; Juliane Stelzer; Anja Sims; Helmut Witzigmann
Journal:  Int J Colorectal Dis       Date:  2011-05-21       Impact factor: 2.571

4.  Neoadjuvant chemoradiotherapy for rectal carcinoma: effects on anastomotic leak rate and postoperative bladder dysfunction after non-emergency sphincter-preserving anterior rectal resection. Results of the Quality Assurance in Rectal Cancer Surgery multicenter observational trial.

Authors:  Benjamin Garlipp; Henry Ptok; Uwe Schmidt; Frank Meyer; Ingo Gastinger; Hans Lippert
Journal:  Langenbecks Arch Surg       Date:  2010-08-15       Impact factor: 3.445

5.  [Individualization of guidelines. Approach for rectal cancer in UICC stages II and III].

Authors:  N Eismann; A Emmermann; C Zornig
Journal:  Chirurg       Date:  2014-02       Impact factor: 0.955

Review 6.  Surgical treatment for rectal cancer: an international perspective on what the medical gastroenterologist needs to know.

Authors:  Rolv-Ole Lindsetmo; Yong-Geul Joh; Conor-P Delaney
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

Review 7.  [The role of magnetic resonance imaging to select patients for preoperative treatment in rectal cancer].

Authors:  Claus Rödel; Rolf Sauer; Rainer Fietkau
Journal:  Strahlenther Onkol       Date:  2009-08-04       Impact factor: 3.621

8.  Magnetic resonance imaging (MRI)-based indication for neoadjuvant treatment of rectal carcinoma and the surrogate endpoint CRM status.

Authors:  Joachim Strassburg; Theo Junginger; Trong Trinh; Olaf Püttcher; Katja Oberholzer; Richard J Heald; Paul Hermanek
Journal:  Int J Colorectal Dis       Date:  2008-07-17       Impact factor: 2.571

9.  Magnetic resonance imaging (MRI) in rectal cancer: a comprehensive review.

Authors:  Michael R Torkzad; Lars Påhlman; Bengt Glimelius
Journal:  Insights Imaging       Date:  2010-08-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.